Skip to content
Announcement:
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Blog Post:
Designing Beyond Tolerability Limits: Advancing GB-4362 Into Clinical Development
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
Menu
Close
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
LinkedIn
X
YouTube
Team Members
Michael Nally
07.13.2026
